ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1421

Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study

Renaud Felten1, Lou KAWKA2, Maxime DUBOIS2, Manuel Ugarte-Gil3, Yurilis Fuentes-Silva4, Matteo PIGA5 and Laurent Arnaud1, 1Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, 2National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, 3Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, 4Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, 5Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy

Meeting: ACR Convergence 2021

Keywords: COVID-19, Systemic lupus erythematosus (SLE), Vaccination

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: COVID-19 Vaccine Experience & Translational Science (1420–1423)

Session Type: Abstract Session

Session Time: 9:15AM-9:30AM

Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic LUPus study (VACOLUP) to evaluate the efficacy and tolerance of the vaccination against SARS-CoV-2 (COVID-19) in SLE. Our main objective was to describe the tolerance of SARS-CoV-2 vaccination in SLE patients, and to assess the risk of post-vaccination flare.

Methods: VACOLUP was designed as a cross-sectional study which consisted of 43 web-based questions. The study took place from March 22, 2021 to May 17, 2021. Main study outcomes included: demographical characteristics; history of COVID-19; history of vaccination against SARS-CoV-2 and tolerance. Self-reported side-effects, medically-confirmed lupus flare or COVID-19 after vaccination were analyzed.

Results: The study included 696 participants (669 [96.1%] women and 27 [3.9%] men), with a median age of 42 years [IQR: 34-51]), from 29 countries. Side-effects were reported by 316 patients (45.4%) after the first dose of COVID-19 vaccine and 181 (52.8%) of those who received a second dose of vaccine. There was no difference in the occurrence of side effects according to gender (p=0.11), age (p=0.08) or by mechanism of action (mRNA vaccines versus others, p=0.69). The type and intensity of side effects are shown in figure 1, being minor or moderate in intensity (i.e., with no consequence on the ability to perform daily tasks) in more than 80% of cases. Taking into account all vaccine doses together (n=1039), side effects required a medical consultation in 81 cases (7.8%), an emergency consultation in 14 cases (1.3%) and an hospitalization in 5 cases (0.5%), including 4 for the occurrence of a SLE flare. A total of 21 patients (3.0%) reported a medically-confirmed lupus flare, typically with predominant musculoskeletal symptoms (90.5%) and fatigue (85.7%). Of note these symptoms were reported to occur after a median delay of 3 days (IQR: 0-29) following COVID-19 vaccination. This led to a change in lupus treatment in 15/21 cases.

Conclusion: Side effects are common but minor or moderate in 80% of the cases. Only 21 (3.0%) self-reported a medically confirmed SLE flare. These flares were mainly represented by musculoskeletal symptoms (90.5%) and fatigue (85.7%) and occurred early after COVID-19 vaccination, suggesting it might be difficult to distinguish between lupus flares and common side-effects of vaccination in SLE patients. Disseminating these reassuring data should therefore help clinicians to increase vaccine coverage in SLE patients.

Figure 1. Type and intensity of side effects after COVID_19 vaccination Cumulative plot showing the proportion of minor, moderate and severe reaction for each adverse event (as self-reported by patients, with severe manifestations defined as affecting the ability to do daily activity)


Disclosures: R. Felten, Janssen, 1, 2, GSK, 2, Pfizer, 6; L. KAWKA, None; M. DUBOIS, None; M. Ugarte-Gil, Pfizer, 5, Janssen, 5; Y. Fuentes-Silva, None; M. PIGA, GSK, 2, Pfizer, 2; L. Arnaud, GlaxoSmithKline, 2, 5, 6, 12, Paid Instructor, Pfizer, 2, Astra-Zeneca, 2.

To cite this abstract in AMA style:

Felten R, KAWKA L, DUBOIS M, Ugarte-Gil M, Fuentes-Silva Y, PIGA M, Arnaud L. Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-tolerance-of-vaccination-against-covid-19-in-patients-with-systemic-lupus-erythematosus-the-international-vacolup-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-tolerance-of-vaccination-against-covid-19-in-patients-with-systemic-lupus-erythematosus-the-international-vacolup-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology